1.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GBG 66, 2011-000553-23, NCT01426880
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EC-FV-06, NCT01170650
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FEDEGYN 02 / 0410-CHIPOR, 2010-023035-42, NCT01376752
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: ACTG A5263, 1U01AI068636, U01CA121947, NCT01435018
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LTS12674, 2011-006246-33, U1111-1127-0888, NCT01593228
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: REV (GINECO-OV214), NCT01111903
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LAPADO-Study, 2007-000924-42, NCT01172223
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MM08-141, NCT01177683
|
|
9.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TL32711-POC-0078-PTL, NCT01188499
|
|
10.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 201102043, NCI-2011-00224, NCT01246063
|
|
11.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IST-CAR-516, NCT01365559
|
|
12.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2B3-101-CR-001, NCT01386580
|
|
13.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GYN10-149, NCT01485874
|
|
14.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PO-MM-PI-0049, PDD-2011, NCT01541332
|
|
15.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PITCH trial, NCT01637532
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: EGF114081, NCT01658358
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IIL-HEART01, 2009-012143-42, NCT01009970
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: FAHG20060216, NCT01051362
|
|
19.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: TTYLD0914, NCT01210768
|
|
20.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 201104170, NCT01281943
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 26866138CAN2026, NCT01328236
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NGR018, 2010-023613-61, NCT01358071
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GMIHO-008/2009_AG56, 2010-018849-59, AG56, NCT01388621
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LD0411, NCT01451580
|
|
25.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GOG-3003, NCT01666444
|